Table 3.
Clinical characteristics and outcomes of cases with MRSA infections.
| Characteristics | Survival (n = 132) | Death (n = 18) | P |
|---|---|---|---|
| DEMOGRAPHICS | |||
| Age | 60 (57–64) | 76 (68–83) | 0.003 |
| Male gender | 98 (74.2) | 13 (72.2 | 1.00 |
| UNDERLYING DISEASE | |||
| Cerebrovascular disease | 25 (18.9) | 4 (22.2) | 0.47 |
| Cancer | 11 (8.3) | 5 (27.8) | 0.01 |
| Respiratory infections | 30 (22.7) | 7 (38.9) | 0.15 |
| Blood stream infections | 6 (4.5) | 0 (0.0) | 0.63 |
| Degenerative diseases | 10 (7.6) | 2 (11.1) | 0.64 |
| Burns | 5 (3.8) | 0 (0.0) | 0.63 |
| Urinary Tract Infections | 4 (3.0) | 0 (0.0) | 1.00 |
| ICU admission | 24 (18.2) | 7 (38.9) | 0.06 |
| Hospital onset | 115 (87.1) | 16 (88.9) | 1.00 |
| Vancomycin treatment | 31 (23.5) | 5 (27.8) | 0.77 |
| ANTIMICROBIAL RESISTANCE | |||
| Erythromycin | 95 (72) | 17 (94.4) | 0.044 |
| Clindamycin | 67 (50.8) | 12 (66.7) | 0.21 |
| TMP-SMX | 95 (72) | 15 (83.3) | 0.40 |
| Rifampin | 77 (58.3) | 12 (66.7) | 0.50 |
| Cefoxitin | 124 (93.9) | 17 (94.4) | 1.00 |
| Nitrofuantoin | 57 (43.2) | 7 (38.9) | 0.73 |
| Ciprofloxacin | 115 (87.1) | 16 (88.9) | 1.00 |
| STRAIN GENOTYPING | |||
| Clonal complex | |||
| CC5 | 34 (25.8) | 14 (77.8) | <0.001 |
| CC239 | 30 (22.7) | 3 (16.7) | 0.76 |
| CC398 | 13 (9.8) | 0 (0.0) | 0.23 |
| CC59 | 18 (13.6) | 1 (5.6) | 0.47 |
| CC88 | 18 (13.6) | 0 (0.0) | 0.13 |
| SCCmec TYPE | |||
| SCCmec II | 37 (28.0) | 13 (72.2) | <0.001 |
| SCCmec III | 29 (22.0) | 3 (16.7) | 0.77 |
| SCCmec IV | 34 (25.8) | 1 (5.6) | 0.07 |
| SCCmec V | 31 (23.5) | 1 (5.6) | 0.12 |
| Spa TYPE | |||
| t002 | 30 (22.7) | 14 (77.8) | <0.001 |
| t037 | 20 (15.2) | 2 (11.1) | 0.75 |
| t437 | 16 (12.1) | 1 (5.6) | 0.49 |
| PVL-positive | 17 (12.9) | 0 (0.0) | 0.13 |
| tst-1-positive | 13 (9.8) | 14 (77.8) | <0.001 |
Values are expressed in N (%) or mean (95% confidence interval). Significant P-values are shown in boldface.